Roth/MKM Starts CG Oncology (CGON) at Buy

Roth/MKM analyst Ben Paluch initiates coverage on CG Oncology (NASDAQ: CGON) with a Buy rating and a price target of $65.00.

The analyst comments "We initiate coverage of CG Oncology with a Buy rating and $65 price target. We anticipate share momentum as cretostimogene approaches a 2H25 BLA submission in BCG-unresponsive, high-risk non-muscle invasive bladder cancer (HR-NMIBC). We view cretostimogene's tolerability as a major differentiator, which could help gain market share from competitors that have tolerability issues in this setting. We believe promising cretostimogene efficacy bodes well for intermediate-risk NMIBC (IR-NMIBC). We see potential for $2B + in 2033 worldwide sales of creostimogene in BCG-unresponsive, HR- and IR-NMIBC."

For an analyst ratings summary and ratings history on CG Oncology click here. For more ratings news on CG Oncology click here.

Shares of CG Oncology closed at $37.74 yesterday.

You May Also Be Interested In

• Goldman Sachs Updates US Conviction List Directors' Cut
• Citi raises Clean Harbors price target to $379 from $378
• These 3 EU chip stocks screen as most de-risked sector bets: UBS